Stockscreener 앱 받기
5.23
3.51%
-0.19
전일 마감가:
$5.42
열려 있는:
$5.42
하루 거래량:
256.51K
Relative Volume:
1.93
시가총액:
$100.28M
수익:
-
순이익/손실:
$-33.63M
주가수익비율:
-2.7348
EPS:
-1.9124
순현금흐름:
$-47.63M
1주 성능:
+4.18%
1개월 성능:
+15.96%
6개월 성능:
+12.72%
1년 성능:
+50.72%
1일 변동 폭
$5.16
$5.45
1주일 범위
$5.02
$5.615
52주 변동 폭
$3.06
$5.615
폴리피드 Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
5.23 | 100.28M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Roth Capital | Buy |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
PolyPid (PYPD) The Citizens Life Sciences Conference 2026 Summary - Quartr
PolyPid (PYPD) Lytham Partners Spring 2026 Investor Conference Summary - Quartr
PolyPid Ltd stock and its pipeline. A closer look at the drug-delivery specialist - ad-hoc-news.de
PYPDPolypid Ltd Latest SEC Filings - Finviz
Price to sales forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Price to earnings forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
Price to book forward of PolyPid Ltd. – NASDAQ:PYPD - TradingView
PYPD Forecast — Price Target — Prediction for 2027 - TradingView
PolyPid Ltd. Actuals & Estimates (NASDAQ:PYPD) - TradingView
PolyPid Ltd. Actuals & Estimates (FWB:2PV) - TradingView
2PV Forecast — Price Target — Prediction for 2027 - TradingView
Lilly’s $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid’s Asset is Hiding in Plain Sight - TipRanks
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PYPD Q1 2026 Earnings: EPS Beat by 20.8% as Company Advances D-PLEX PlatformReturn On Equity - dars.gov.et
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Raises Target Price to $9 - Moomoo
PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PolyPid Ltd (PYPD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PolyPid Ltd (PYPD) Valuation: PE, PB & Fair Value Analysis - TradingKey
PolyPid Ltd (PYPD) Institutional Confidence - TradingKey
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PolyPid Ltd Stock (US70450B1035): modest move as market awaits next catalyst - AD HOC NEWS
PYPD Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineNew Analyst Coverage - newsline.com
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PolyPid Ltd. (PYPD) Shares Edge Higher as Support Holds, Resistance in FocusTRIN Signal - newsline.com
PYPD Technical Analysis & Stock Price Forecast - Intellectia AI
PolyPid schedules annual and extraordinary shareholder meeting for July 15 By Investing.com - Investing.com Nigeria
PolyPid Sets July 15, 2026 Shareholder Meeting to Vote on Board, Auditor and Equity Grants - TipRanks
PolyPid schedules annual and extraordinary shareholder meeting for July 15 - Investing.com India
PolyPid (PYPD) schedules July 15, 2026 meeting on director, auditor and option approvals - Stock Titan
When Can We Expect A Profit From PolyPid Ltd. (NASDAQ:PYPD)? - simplywall.st
PYPD Q1 2026 Earnings: Narrower-than-Expected Loss Drives 20.81% Surprise; Shares Dip Despite ProgressForward EPS Estimate - newsline.com
PolyPid Ltd. (PYPD) Shares Slide 6.8% as Stock Approaches Key Support at $4.27Factor Valuation - newsline.com
PYPD Q1 2026 Earnings: Pre-Revenue Biotech Narrows Loss, Stock Slides on No Commercial MilestonesQuarterly Financial Update - newsline.com
PolyPid Stock Barely Moves After FDA Filing, But a 2027 Decision Now Looms - Bez Kabli
PYPD Q1 2026 Earnings: Narrower Loss Surprises as Key Pipeline Progress Remains on TrackGuidance Accuracy Score - newsline.com
PYPD Q1 2026 Earnings: Narrower Than Expected Loss Drives Positive Surprise Despite Stock DipEarnings Revision Downgrade - newsline.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD) - The Globe and Mail
PolyPid Completes Rolling NDA Submission to FDA for D-PLEX100 - marketscreener.com
PolyPid Files NDA with FDA for Lead Infection-Prevention Drug D-PLEX100 - TipRanks
PolyPid completes NDA submission for surgical infection drug - Investing.com
PolyPid completes NDA submission for surgical infection drug By Investing.com - Investing.com Canada
PolyPid (Nasdaq: PYPD) files FDA NDA for D-PLEX100 infection drug - Stock Titan
New surgical infection drug from PolyPid heads to FDA decision in 2027 - Stock Titan
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ - GlobeNewswire
PolyPid Ltd stock (US70450B1035): Nasdaq-listed biotech sees quiet trading as investors await next c - AD HOC NEWS
PYPD Q1 2026 Earnings: Narrower Net Loss Beats Expectations as Clinical Pipeline AdvancesFinancial Data - The Legal Advocate
PolyPid Ltd. (PYPD) Q1 2026 Earnings: Narrower-than-Expected Loss on Strong Expense ControlMargin Guidance - The Legal Advocate
PolyPid Ltd. (PYPD) Edges Lower, Testing Key Support Near $4.52Delta Hedging - The Legal Advocate
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):